Identification of a Btk mutation in a dysgammaglobulinemic patient with reduced B cells: XLA diagnosis or not?

Simona Graziani, Gigliola Di Matteo, Luigi Benini, Silvia Di Cesare, Maria Chiriaco, Loredana Chini, Marco Chianca, Fosca De Iorio, Maria La Rocca, Roberta Iannini, Stefania Corrente, Paolo Rossi, Viviana Moschese

Research output: Contribution to journalArticle

Abstract

The identification of a Btk mutation in a male patient with <2% CD19+ B cells warrants making the diagnosis of X-linked Agammaglobulinemia (XLA). Herein we report the case of a 31 year-old male with a gradual decline of peripheral B lymphocytes and low IgA and IgM but normal IgG levels. His clinical history revealed recurrent respiratory and skin infections, sclerosing cholangitis and chronic obstructive pancreatitis. Molecular studies revealed a novel aminoacidic substitution in Btk protein (T316A). His mother, maternal aunts and a maternal female cousin were heterozygotes for the same Btk mutation and were variably affected with pulmonary emphysema. This is a puzzling case where the patient's clinical history and laboratory findings divorce molecular genetics. Either this case confirms the variable expressivity of XLA disease or the T316A change in Btk SH2 domain is a novel non-pathogenic mutation and another unknown gene alteration is responsible for the disease.

Original languageEnglish
Pages (from-to)322-328
Number of pages7
JournalClinical Immunology
Volume128
Issue number3
DOIs
Publication statusPublished - Sep 2008

Fingerprint

B-Lymphocytes
Mothers
Mutation
Sclerosing Cholangitis
Pulmonary Emphysema
src Homology Domains
Divorce
Chronic Pancreatitis
Heterozygote
Respiratory Tract Infections
Immunoglobulin A
Immunoglobulin M
Molecular Biology
Immunoglobulin G
Skin
Genes
Bruton type agammaglobulinemia
Agammaglobulinaemia tyrosine kinase

Keywords

  • Btk
  • Chronic obstructive pancreatitis
  • Sclerosing cholangitis
  • XLA

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Identification of a Btk mutation in a dysgammaglobulinemic patient with reduced B cells : XLA diagnosis or not? / Graziani, Simona; Di Matteo, Gigliola; Benini, Luigi; Di Cesare, Silvia; Chiriaco, Maria; Chini, Loredana; Chianca, Marco; De Iorio, Fosca; La Rocca, Maria; Iannini, Roberta; Corrente, Stefania; Rossi, Paolo; Moschese, Viviana.

In: Clinical Immunology, Vol. 128, No. 3, 09.2008, p. 322-328.

Research output: Contribution to journalArticle

Graziani, S, Di Matteo, G, Benini, L, Di Cesare, S, Chiriaco, M, Chini, L, Chianca, M, De Iorio, F, La Rocca, M, Iannini, R, Corrente, S, Rossi, P & Moschese, V 2008, 'Identification of a Btk mutation in a dysgammaglobulinemic patient with reduced B cells: XLA diagnosis or not?', Clinical Immunology, vol. 128, no. 3, pp. 322-328. https://doi.org/10.1016/j.clim.2008.05.012
Graziani, Simona ; Di Matteo, Gigliola ; Benini, Luigi ; Di Cesare, Silvia ; Chiriaco, Maria ; Chini, Loredana ; Chianca, Marco ; De Iorio, Fosca ; La Rocca, Maria ; Iannini, Roberta ; Corrente, Stefania ; Rossi, Paolo ; Moschese, Viviana. / Identification of a Btk mutation in a dysgammaglobulinemic patient with reduced B cells : XLA diagnosis or not?. In: Clinical Immunology. 2008 ; Vol. 128, No. 3. pp. 322-328.
@article{46d3cb89a261461f8842b29ea4bfd61d,
title = "Identification of a Btk mutation in a dysgammaglobulinemic patient with reduced B cells: XLA diagnosis or not?",
abstract = "The identification of a Btk mutation in a male patient with <2{\%} CD19+ B cells warrants making the diagnosis of X-linked Agammaglobulinemia (XLA). Herein we report the case of a 31 year-old male with a gradual decline of peripheral B lymphocytes and low IgA and IgM but normal IgG levels. His clinical history revealed recurrent respiratory and skin infections, sclerosing cholangitis and chronic obstructive pancreatitis. Molecular studies revealed a novel aminoacidic substitution in Btk protein (T316A). His mother, maternal aunts and a maternal female cousin were heterozygotes for the same Btk mutation and were variably affected with pulmonary emphysema. This is a puzzling case where the patient's clinical history and laboratory findings divorce molecular genetics. Either this case confirms the variable expressivity of XLA disease or the T316A change in Btk SH2 domain is a novel non-pathogenic mutation and another unknown gene alteration is responsible for the disease.",
keywords = "Btk, Chronic obstructive pancreatitis, Sclerosing cholangitis, XLA",
author = "Simona Graziani and {Di Matteo}, Gigliola and Luigi Benini and {Di Cesare}, Silvia and Maria Chiriaco and Loredana Chini and Marco Chianca and {De Iorio}, Fosca and {La Rocca}, Maria and Roberta Iannini and Stefania Corrente and Paolo Rossi and Viviana Moschese",
year = "2008",
month = "9",
doi = "10.1016/j.clim.2008.05.012",
language = "English",
volume = "128",
pages = "322--328",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Identification of a Btk mutation in a dysgammaglobulinemic patient with reduced B cells

T2 - XLA diagnosis or not?

AU - Graziani, Simona

AU - Di Matteo, Gigliola

AU - Benini, Luigi

AU - Di Cesare, Silvia

AU - Chiriaco, Maria

AU - Chini, Loredana

AU - Chianca, Marco

AU - De Iorio, Fosca

AU - La Rocca, Maria

AU - Iannini, Roberta

AU - Corrente, Stefania

AU - Rossi, Paolo

AU - Moschese, Viviana

PY - 2008/9

Y1 - 2008/9

N2 - The identification of a Btk mutation in a male patient with <2% CD19+ B cells warrants making the diagnosis of X-linked Agammaglobulinemia (XLA). Herein we report the case of a 31 year-old male with a gradual decline of peripheral B lymphocytes and low IgA and IgM but normal IgG levels. His clinical history revealed recurrent respiratory and skin infections, sclerosing cholangitis and chronic obstructive pancreatitis. Molecular studies revealed a novel aminoacidic substitution in Btk protein (T316A). His mother, maternal aunts and a maternal female cousin were heterozygotes for the same Btk mutation and were variably affected with pulmonary emphysema. This is a puzzling case where the patient's clinical history and laboratory findings divorce molecular genetics. Either this case confirms the variable expressivity of XLA disease or the T316A change in Btk SH2 domain is a novel non-pathogenic mutation and another unknown gene alteration is responsible for the disease.

AB - The identification of a Btk mutation in a male patient with <2% CD19+ B cells warrants making the diagnosis of X-linked Agammaglobulinemia (XLA). Herein we report the case of a 31 year-old male with a gradual decline of peripheral B lymphocytes and low IgA and IgM but normal IgG levels. His clinical history revealed recurrent respiratory and skin infections, sclerosing cholangitis and chronic obstructive pancreatitis. Molecular studies revealed a novel aminoacidic substitution in Btk protein (T316A). His mother, maternal aunts and a maternal female cousin were heterozygotes for the same Btk mutation and were variably affected with pulmonary emphysema. This is a puzzling case where the patient's clinical history and laboratory findings divorce molecular genetics. Either this case confirms the variable expressivity of XLA disease or the T316A change in Btk SH2 domain is a novel non-pathogenic mutation and another unknown gene alteration is responsible for the disease.

KW - Btk

KW - Chronic obstructive pancreatitis

KW - Sclerosing cholangitis

KW - XLA

UR - http://www.scopus.com/inward/record.url?scp=49149087892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49149087892&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2008.05.012

DO - 10.1016/j.clim.2008.05.012

M3 - Article

C2 - 18708023

AN - SCOPUS:49149087892

VL - 128

SP - 322

EP - 328

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -